title: The influence of gonadal function and the effect of gonadal suppression treatment on final height in growth hormone (GH)-treated GH-deficient children.
abstract: One hundred and sixty-one children with idiopathic GH deficiency who received GH treatment were followed until they reached their final height. Final height was found to be influenced by gonadal function. In 108 patients who had spontaneous puberty (91 boys and 17 girls; group A), the mean final height was 151.8 +/- 6.6 (+/- SD) cm in boys and 141.7 +/- 7.4 cm in girls. In 29 patients with combined GH and gonadotropin deficiency (23 boys and 6 girls; group C), whose pubertal development was induced artificially at age 19.5 +/- 2.1 yr in the boys and 18.6 +/- 1.8 yr in the girls, the mean final height was 163.7 +/- 3.9 cm in boys and 151.0 +/- 5.1 cm in girls. The differences in final height between groups A and C were significant in both boys and girls. The shorter final height in group A was caused by the shorter pubertal duration and smaller pubertal height gain than those in normal children. In 24 patients (17 boys and 7 girls; group B) who developed early signs of puberty, gonadal suppression therapy with cyproterone acetate and/or medroxyprogesterone acetate was given. The mean SD score of the final height in these 24 patients was -2.1 +/- 0.6, significantly higher than that in group A. This beneficial effect of gonadal suppression treatment on final height was caused by increases in the duration of puberty and the pubertal height gain.
authors.affiliation: Division of Endocrinology and Metabolism, National Children's Hospital, Tokyo, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Hibi
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: A
authors.initials: A
authors.lastname: Tanae
authors.forename: J
authors.initials: J
authors.lastname: Kagawa
authors.forename: N
authors.initials: N
authors.lastname: Hashimoto
authors.forename: A
authors.initials: A
authors.lastname: Yoshizawa
authors.forename: K
authors.initials: K
authors.lastname: Shizume
mesh_terms: D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D002648:Child; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017373:Cyproterone Acetate; D004393:Dwarfism, Pituitary / Q000188:drug therapy*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D006062:Gonadotropins / Q000008:administration & dosage / Q000172:deficiency* / Q000502:physiology; D013006:Growth Hormone / Q000008:administration & dosage / Q000172:deficiency*; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D010053:Ovary / Q000187:drug effects; D011627:Puberty / Q000187:drug effects*; D013737:Testis / Q000187:drug effects
chemical_list: D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D013006:Growth Hormone; D003534:Cyproterone; D008525:Medroxyprogesterone